Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B): a multicentre, open-label, randomised, phase 3 trial.

已完结 20 由 necromme 发布于 2026/11/12 13:20:01

DOI:10.1016/S2352-3026(23)00037-6
作者：Alok Srivastava,?Savita Rangarajan,?Kaan Kavakli,?Robert Klamroth,?Gili Kenet,?Liane Khoo,?Chur-Woo You,?Weiqun Xu,?Niel Malan,?Laurent Frenzel,?Catherine N Bagot,?Oleksandra Stasyshyn,?Chia-Yau Chang
文献类型：期刊论文
补充材料：只需要正文

其它数据库

Abstract：Background: Fitusiran, a subcutaneous investigational siRNA therapeutic, targets antithrombin with the goal of rebalancing haemostasis in people with haemophilia A or haemophilia B, regardle

应助信息

49分钟前

一羊万洗

761eb547de5911f1a48e208810ba6e4f.pdf 已采纳

54分钟前

Book学术机器人

2026/11/12 13:20:01 未找到该文献，机器人已退出，请等待人工下载

2026/11/12 13:20:01 Book学术AI机器人收到请求，开始寻找文献

2026/11/12 13:20:01 已向机器人发送请求

54分钟前

necromme 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierLPS-enriched interaction drives spectrum conversion in antimicrobial peptides: Design and optimization of AA16 derivatives for targeting gram-negative bacteria